97191 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE
#302METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER
#303Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
#304NOVEL FUSION PROTEIN AND USE OF SAME
#305BINDING MOLECULES FOR BCMA AND CD3
#306Immunoglobulin variable domains
#307ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
#308Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)
#309ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#310METHODS OF DETECTING AND PREDICTING BREAST CANCER
#311Dosing regimen of combination of ANTICD20 and anti-BlyS antibodies
#312Rank Pathway Inhibitors in Combination with CDK Inhibitors
#313Antibodies that specifically bind to TL1A and methods of treating gastrointestinal disease
#314Bispecific Antibodies for use in treatment of NLRC4-GOF inflammasomapathy
#315High concentration anti-blys pharmaceutical formulations
#316Methods of Engineering Surface Charge for Bispecific Antibody Production
#317NGF Antagonists for Medical Use
#318Kit comprising contiguous nucleobases, including position 76, of RS5745994
#319POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L
#320Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole
#321METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES
#322Immunoglobulin variable domains
#323ANTI-CD40 ANTIBODIES AND USES THEREOF
#324LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES
#325TRAILshort antibody and methods of use
#326Immunoglobulin variable domains
#327TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#328ANTI-OX40 ANTIBODIES AND THEIR USES
#329HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS
#330ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
#331miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells
#332ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
#333GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#334ANTI-CD137L ANTIBODIES AND METHODS OF USING SAME
#335BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS
#336ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
#337Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
#338Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#339Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#340CANCER ANTIGEN TARGETS AND USES THEREOF
#341BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#342ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
#343Binding molecules for BCMA and CD3
#344ANTIBODY CONSTANT REGION VARIANT
#345Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
#346METHODS FOR IDENTIFYING EPITOPES AND PARATOPES
#347METHODS, SYSTEMS, AND KITS FOR TREATING INFLAMMATORY DISEASE TARGETING IL18R1
#348CHIMERIC ANTIGEN RECEPTOR FACTORIES AND METHODS OF USE THEREOF
#349Library of antigen-binding molecules including modified antibody variable region
#350Fusion constructs and methods of using thereof
#351Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#352Protein signatures for distinguishing between bacterial and viral infections
#353STABLE LIQUID COMPOSITION COMPRISING PROTEIN
#354Genetically modified natural killer cells for CD70-directed cancer immunotherapy
#355AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
#356METHODS FOR TREATING IMMUNE RELATED OCULAR DISORDERS
#357Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#358MUTANT OF RANKL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING OSTEOPOROSIS
#359Antibodies, uses and methods
#360METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS
#361ANTI-CD70 ANTIBODIES AND USES THEREOF
#362METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
#363GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND THERAPEUTIC USES THEREOF
#364ANTIBODIES AGAINST TL1A AND USES THEREOF
#365METHOD OF PRODUCING A VACCINE COMPOSITION AND USES THEREOF
#366ANTIBODY MOLECULES TO APRIL AND USES THEREOF
#367COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#368Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
#369Treatment of autoimmune disorders with CD154 antibodies
#370RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#371METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD154 ANTIBODY
#372MULTISPECIFIC ANTIBODIES
#373ANTIBODY CONSTRUCTS FOR CD70 AND CD3
#374Antigen binding molecules that bind light
#375Anti-CXCL13 antibodies for treating autoimmune diseases and cancer
#376MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#377CD70 binding molecules and methods of use thereof
#378ANTI-GITR ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#379Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
#380Immunoglobulin variable domains
#381Immunoglobulin variable domains
#382Methods and compositions for treating cancer
#383Immunoglobulin variable domains
#384MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
#385LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
#386Anti-NGF Antibodies and Methods Thereof
#387Methods and compositions for treating cancer
#388NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
#389Methods and systems for selection and treatment of patients with inflammatory diseases
#390COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM
#391MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF
#392Method of treating IgA nephropathy by administering altered antibodies which bind human a proliferation-inducing ligand (APRIL) protein
#393Anti-NGF Antibodies and Methods Thereof
#394Canine anti-NGF antibodies and methods of treating pain thereof
#395Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
#396Felinized anti-NGF antibodies and methods of treating pain
#397Anti-NGF Antibodies and Methods Thereof
#398Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies
#399Proteins specific for BAFF and B7RP1 and uses thereof
#400Humanized anti-NGF antibodies and methods of treating pain thereof
#401Method for the prognosis and treatment of cancer metastasis
#402Nucleic acids encoding a canine antibody which binds nerve growth factor and vectors and host cells thereof
#403TL1A antibodies and methods of treatment
#404POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L
#405EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS
#406LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT
#407NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#408Androgen Receptor Modulator And Uses Thereof
#409METHODS FOR MAKING STABLE PROTEIN COMPOSITIONS
#410Methods, apparatuses, and systems for tracking freight
#411ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE
#412Methods of immunosuppression comprising administering an anti-CD154 antibody
#413Halogenated xanthene composition and method for treating hematologic cancers
#414Therapeutic treatment of breast cancer based on c-MAF status
#415Nucleic acids encoding an anti-CD154 antibody comprising E269R and K322A mutations
#416RANKL-specific agent for treating metastatic disease
#417Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
#418Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
#419ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
#420Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
#421Anti-CD137 antibodies and methods of use thereof
#422Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
#423ANTI-CD252 ANTIBODIES, CONJUGATES, AND METHODS OF USE
#424NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#425Nucleic acids encoding anti-OX40L antibodies
#426Immunoglobulin variable domains
#427METHODS OF TREATING CANCER WITH DENDRITIC CELL MOBILIZING AGENTS
#428OPTIMIZED ANTI-TL1A ANTIBODIES
#429Antibodies with modulated glycan profiles
#430Multi-specific ligand binders
#431Methods and compositions for treating cancer
#432METHOD FOR TREATING SEIZURES
#433METHOD FOR EFFICIENTLY ACTIVATING AND EXPANDING T CELLS
#434Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
#435Decreased adhesivity receptor-targeted nanoparticles for Fn14-positive tumors
#436ANTI-OX40 ANTIBODIES AND THEIR USES
#437Humanized Anti-CD70 Binding Agents and Uses Thereof
#438Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
#439Anti-CXCL13 antibodies
#440Method, apparatus and systems for tracking freight
#441Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
#442COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
#443Gene combination capable of high-efficiency expression of recombinant human nerve growth factor
#444Stable Dual Variable Domain Immunoglobulin Protein Formulations
#445FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#446Precision Medicine Method for Cancer Immunotherapy
#447ACID-MEDIATED ASSAY FOR ANALYZING LIGAND-DRUG CONJUGATES
#448ANTIBODIES TO OPGL
#449Formulations comprising human anti-RANKL monoclonal antibodies, and methods of using the same
#450SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#451Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#452Compositions and methods for selective protein degradation
#453Antigen-binding molecule containing modified antibody variable region
#454Antibody molecules to a proliferation-inducing ligand (APRIL)
#455Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#456Anti-CD70 chimeric antigen receptors
#457Methods of administering anti-OX40 antibodies
#458Nucleic acids encoding anti-CD154 antibodies
#459Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)
#460ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#461Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
#462Fusion protein comprising an FGF-18 moiety
#463Antibody-drug conjugate
#464Anti-CD40L antibodies
#465Vectors comprising nucleic acids encoding anti-OX40 antibodies
#466ANTI-CD40 ANTIBODIES AND USES THEREOF
#467FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#468ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
#469Optimized anti-TL1A antibodies
#470High concentration protein formulations with reduced viscosity
#471HUMAN IMMUNE THERAPIES USING A CD27 AGONIST ALONE OR IN COMBINATION WITH OTHER IMMUNE MODULATORS
#472Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease
#473METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
#474Immunoglobulin variable domains
#475Therapeutic anti-CD40 ligand antibodies
#476BLyS antibody formulation
#477Stable IGG4 Based Binding Agent Formulations
#478Methods of treating autoimmune disease using a domain antibody directed against CD40L
#479Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#480ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#481Methods and compositions for targeting tissue lesions
#482Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
#483Cancer antigen targets and uses thereof
#484ANTI-OX40 ANTIBODIES AND THEIR USES
#485Anti-GARP protein
#486COMBINATION THERAPY WITH ICOS AGONIST AND OX40 AGONIST TO TREAT CANCER
#487Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
#488ASSAYS FOR ASSESSING NEUTRALIZING ANTIBODIES LEVELS IN SUBJECTS TREATED WITH A BIOLOGICAL DRUG AND USES THEREOF IN PERSONALIZED MEDICINE
#489ANTIBODIES TO OPGL
#490EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS
#491Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#492Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody
#493Anti-TIGIT antigen-binding proteins and methods of use thereof
#494FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS
#495Composition comprising B regulatory cells
#496Method of screening for anti-GARP antibodies
#497ANTIBODIES THAT BIND TO TL1A AND THEIR USES
#498Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
#499Method for producing B cell population and method for producing monoclonal antibody using same
#500STABILIZED ANTIBODY PROTEIN SOLUTIONS
#501VARIANT TARGET BINDING AGENTS AND USES THEREOF
#502METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS
#503ANTI-NGF COMPOSITIONS AND USE THEREOF
#504OX40-binding polypeptides and uses thereof
#505Anti-GDF15 antibodies, compositions and methods of use
#506Anti-OX40 antibodies and their uses
#507PANTIDS FOR TREATMENT OF AUTOIMMUNE DISORDERS
#508METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES
#509BAFF selective binding compounds and related methods
#510Treatment of multiple sclerosis and neuromyelitis optica
#511TRAILshort antibody and methods of use
#512Nucleic acids encoding anti-OX40 antibodies
#513Anti-CD70 antibody drug conjugates
#514Targeted pyrrolobenzodiazapine conjugates
#515Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
#516Methods and compositions relating to ex vivo culture and modulation of T cells
#517ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
#518Decreased adhesivity receptor-targeted nanoparticles for Fn14-positive tumors
#519Antigen binding molecules that bind LIGHT
#520Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties and related therapies
#521ANTI-RANKL ANTIBODIES AND METHODS OF USE
#522Anti-BAFF antibodies
#523Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
#524PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D
#525Anti-OX40 antibodies
#526Anti-RANKL antibodies and uses thereof
#527Anti-NGF antibodies and methods thereof
#528ANTIBODIES, USES & METHODS
#529Antibodies, combinations comprising antibodies, biomarkers, uses and methods
#530Antibodies to CD70
#531Re-directed immunotherapy
#532Recombinant chimeric antigen receptor gene and use thereof
#533Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
#534CD70 combination therapy
#535BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
#536Antibodies specific for CD70 and their uses
#537Chimeric antigen receptors targeting CD70
#538LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES
#539ANTI-CANCER COMBINATION TREATMENT
#540METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
#541BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#542ANTIBODY CONSTANT REGION VARIANT
#543METHODS OF PURIFYING AND QUALIFYING ANTIBODIES
#544Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
#545Bi-functional chimeric proteins and uses thereof
#546TL1A antibodies and uses thereof
#547Method for the diagnosis, prognosis and treatment of lung cancer metastasis
#548Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
#549Methods of treatment using activatable anti-EGFR antibodies
#550TREATMENT FOR ACUTE MYELOID LEUKEMIA
#551Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseases
#552Antibody polypeptides that antagonize CD40L
#553Antagonistic anti-OX40L antibodies and methods of their use
#554Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies
#555Antibody molecules to a proliferation-inducing ligand (APRIL)
#556Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
#557Antibodies specific for DR5 and methods of use
#558Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
#559Cation exchange chromatography wash buffer
#560Methods of engineering surface charge for bispecific antibody production
#561NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE
#562Antibody against a complex between human GARP and latent TGF-β
#563Triple combination antibody therapies
#564Antibody-drug conjugate
#565Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#566Methods and Compositions for Treating Conditions of the Eye
#567Single variable domain antibodies against OX40L, constructs and therapeutic use
#568VARIANT ANTIBODIES FOR SITE-SPECIFIC CONJUGATION
#569Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
#570Polypeptides inhibiting CD40L
#571Anti-TIGIT antibodies and methods of use thereof
#572TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#573Cancer antigen targets and uses thereof
#574ANTI-OX40 ANTIBODIES AND THEIR USES
#575Anti-CD137 antibodies and methods of use thereof
#576Polynucleotides encoding anti-CD40 antibodies
#577High concentration protein formulations with reduced viscosity
#578Method, apparatus and systems for tracking freight
#579Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
#580Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit
#581FOCUSED INTERFERON IMMUNOTHERAPY FOR TREATMENT OF CANCER
#582Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
#583Method, apparatus and systems for tracking freight
#584Human CD30 Ligand Antigen Binding Proteins
#585METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH17 MEDIATED DISEASES
#586Library of antigen-binding molecules including modified antibody variable region
#587Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
#588ANTIBODY FORMULATION
#589Kit for immunological detection of TNF-alpha, sTNFR1 and IL-8 in prostate cancer
#590HUMAN IMMUNE THERAPIES USING A CD27 AGONIST IN COMBINATION WITH ANOTHER IMMUNE AGONIST TO TREAT CANCER
#591Methods of treating autoimmune disorders using a combination of anti-CD20 and anti-blys antibodies
#592Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed
#593Core constructs and their uses in configuring pharmaceutical molecules
#594Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies
#595FC VARIANTS
#596ANTI-FIBROTIC EFFECT OF CD70
#597Assays for detecting T cell immune subsets and methods of use thereof
#598TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#599CD70 binding molecules and methods of use thereof
#600Anti-CD70 chimeric antigen receptors